Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.60 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22171340 | 0.89 | SIRT6 (0.59) | MAPTSIRT6MEN1KMT2AALDH1A1 | |
| SCHEMBL27355 | 0.87 | MAPT (0.60) | MAPTSIRT6MEN1KMT2AALDH1A1 | |
| SCHEMBL15893974 | 0.82 | MAPT (0.69) | MAPTSIRT6MEN1KMT2AALDH1A1 | |
| SCHEMBL27194288 | 0.82 | MAPT (0.61) | MAPTSIRT6MEN1KMT2AALDH1A1 | |
| SCHEMBL27717 | 0.81 | AKR1C3 (0.52) | MAPTSIRT6MEN1KMT2AALDH1A1 | |
| SCHEMBL27789 | 0.81 | MAPT (0.64) | MAPTSIRT6MEN1KMT2AALDH1A1 | |
| SCHEMBL6714560 | 0.81 | MEN1 (0.73) | MAPTSIRT6MEN1KMT2AALDH1A1 | |
| SCHEMBL7293241 | 0.80 | MAPT (0.62) | MAPTSIRT6MEN1KMT2AALDH1A1 | |
| SCHEMBL6992319 | 0.80 | SIRT6 (0.64) | MAPTSIRT6MEN1KMT2AALDH1A1 | |
| SCHEMBL27832 | 0.80 | SIRT6 (0.59) | MAPTSIRT6MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114853846-A | Androgen receptor degradation agent and application thereof | 苏州国匡医药科技有限公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-2407466-B1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-9062035-B2 | Piperazine compound capable of inhibiting prostaglandin D synthase | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-8865714-B2 | Piperazine compound capable of inhibiting prostaglandin D synthase | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-10-21 | — | — | US | disclosed |
| US-20140128394-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-05-08 | — | — | US | disclosed |
| EP-2407466-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | Taiho Pharmaceutical Co., Ltd. (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-20110319413-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128394-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | PTGDR, PTGS1, PTGDR2 | MAPT 4854/4885SIRT6 863/4885MEN1 3950/4885 |
| US-20110319413-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | PTGS1, PTGDR, PTGIS | MAPT 4854/4885SIRT6 1129/4885MEN1 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.